GlaxoSmithKline is Undervalued, say Analysts

Despite poor sales in China, analysts say that pharmaceutical giant Glaxo is still well-positioned and has several potential blockbuster drugs in the pipeline

Damien Conover, CFA 28 October, 2013 | 4:19PM
Facebook Twitter LinkedIn

GlaxoSmithKline (GSK) reported third-quarter results largely in line with our expectations and those of consensus. However, top-line growth was a little soft due to higher-than-expected sales declines in China resulting from the on-going government investigation, offset on the bottom line by better-than-expected cost cuts.

We don't expect any significant changes to our fair value estimate, which at the current market price suggests the stock is undervalued. Core to our valuation and wide moat rating is the company's pipeline, which continues to make strong strides.

Finally transitioning from the minor innovation of a decade ago, Glaxo's pipeline is poised to accelerate growth over the next several years. The company's new respiratory drugs Anoro and Relvar not only offer advancements over current therapies, but also create a pathway for the company to reduce its dependence on Advair, which will eventually face generic competition.

Further, the company's new HIV drug Tivicay should help the company regain market share. However, we expect the launch trajectory to be slower with these drugs as the company battles challenging reimbursement negotiations and well-entrenched competition.

Cost-cutting is running ahead of our expectations. Both research and development and selling, general, and administrative expense fell faster than we expected. While we like to see the productivity improvements, we are somewhat concerned to see R&D as a percentage of sales fall to 12%, a low mark relative to peers. For Glaxo to continue to see strong pipeline progress, we would expect to see an increase in R&D spending.

Turning to China, government investigations of improper marketing caused sales in the region to fall 61% year over year, a more severe drop than we had expected. We plan to slightly lower our Chinese sales forecast in the near term, but continue to expect Glaxo will rebound in China over the longer term as the region is critical for long-term growth.

This is an excerpt from a Morningstar analyst report. For the full report, Premium subscribers can click here

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
GSK PLC1,733.50 GBX0.29Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures